Stoke Therapeutics Announces Plans To Present New Data That Support Zorevunersen As Potentially The First Disease-Modifying Medicine For Dravet Syndrome At The American Epilepsy Society 2024 Annual Meeting
Stoke Therapeutics Announces Plans To Present New Data That Support Zorevunersen As Potentially The First Disease-Modifying Medicine For Dravet Syndrome At The American Epilepsy Society 2024 Annual Meeting
– Company to host a virtual educational event for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific) –
公司将于美国东部时间12月9日上午8:30（太平洋时间凌晨5:30）举办一场虚拟的教育活动，面向投资者和研究分析师。
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced several presentations at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6 – 10, in Los Angeles, California. In addition, the Company will host a virtual event with discussions led by leading clinicians and patient advocates for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific). The Company is advancing zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc.（纳斯达克股票代码：STOK）是一家专注于利用RNA药物挖掘人体潜力恢复蛋白质表达的生物技术公司。该公司今天宣布将在加利福尼亚洛杉矶举行的2024年美国癫痫学会（AES）年会上进行多个演示。此外，公司还将于12月6日至10日举办一场虚拟活动，旨在讨论受领先临床医生和患者倡导者引领的议题，以供投资者和研究分析师参与。该公司正在推进zorevunersen作为治疗Dravet综合征的潜在首个疾病修饰药物。
